

May 18, 2023

<Provider Name>
<Provider Address 1>
<Provider Address 2>
<City> <State> zipcode5-zipcode4

Dear Pharmacy Providers and Medicaid Health Plans:

RE: Clarification of Medication Therapy Management (MTM) Billing Requirements and Language

The purpose of this letter is to provide clarification of MTM policy language and billing requirements. First, MDHHS is clarifying that the term telemedicine will be used in future publications instead of telepractice. Second, the modifier GT will no longer be used to identify MTM services provided through telepractice. Instead, effective May 12, 2023, place of service modifier 95 should be used in accordance with bulletin [MMP 23-10](#), Telemedicine Policy Post-COVID-19 Public Health Emergency.

Telemedicine

Bulletin [MMP 23-10](#) utilizes the term “telemedicine” throughout. Additionally, recent updates to the [MDHHS Medicaid Provider Manual](#) have replaced the term “telepractice” with the term telemedicine. Telemedicine is the use of telecommunication technology to connect a beneficiary with a Medicaid-enrolled health care professional in a different location. The original MTM policy, [MSA 17-09](#), utilized the former term, telepractice. MDHHS is clarifying that the term telemedicine will be used in future publications instead of telepractice.

Place of Service (POS), Modifier 95

The original MTM policy, [MSA 17-09](#), billing requirements indicated that modifier GT should be used for each procedure code for MTM services provided through telepractice. In accordance with bulletin [MMP 23-10](#), audio/visual telemedicine services, as allowable on the telemedicine fee schedule and submitted on the professional invoice, must be reported with the POS code that would be reported as if the beneficiary were in-person for the visit along with modifier 95 - "Synchronous Telemedicine Service rendered via a real-time interactive audio and video telecommunications system". Telemedicine claims without these indicators may be denied.


All other claim billing requirements of bulletin [MSA 17-09](#) remain in place.

L 23-39

Any other questions can be directed to Vicki Goethals via email at GoethalsV@michigan.gov.

An electronic version of this document is available at www.michigan.gov/medicaidproviders
>> Policy, Letters & Forms.

Sincerely,

A handwritten signature in cursive script that reads "Sarah Q. Hanley".

Farah Hanley
Senior Chief Deputy Director for Health